Enochian BioSciences Announces the Appointment of Executive Vice President of Research and Development with 25 years of Industry Experience
20 avr. 2022 07h00 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, April 20, 2022 (GLOBE NEWSWIRE) -- Enochian BioSciences (NASDAQ: ENOB). Enochian BioSciences Inc., a company focused on gene-modified cellular and immunotherapies in infectious diseases...
Enochian BioSciences Announces Appointment of Senior Vice President for Clinical Operations with 32 Years’ Experience at Pfizer
07 avr. 2022 06h00 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, April 07, 2022 (GLOBE NEWSWIRE) -- Enochian BioSciences, Inc., (NASDAQ: ENOB), a company focused on gene-modified cellular and immunotherapies in infectious diseases and cancer,...
Enochian BioSciences Inventor and Co-Founder Presents Data on Novel Clinical Approaches as the Invited, Concluding Plenary Speaker at the Innate Killer Summit
05 avr. 2022 06h00 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, April 05, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene-modified cellular and immune therapies for infectious diseases and cancer, announced...
Enochian BioSciences and Caring Cross Announce a Partnership to Potentially Increase the Effectiveness of a CAR-T Approach for HIV Cure Currently Being Studied in Humans
15 mars 2022 07h00 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, March 15, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- Enochian BioSciences, a company focused on gene modified cellular and immune therapies for infectious diseases and cancer, has...
Enochian BioSciences Announces Scientific Presentation at World Vaccine Conference on Promising Human and Laboratory Data to Potentially Treat Solid Tumors
03 déc. 2021 07h00 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, Dec. 03, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today...
Enochian BioSciences Announces the Successful Completion of an FDA Pre-IND for a Potential Cure for HIV: The Second Pre-IND in 1 month
18 oct. 2021 07h00 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, Oct. 18, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today...
Scientific Advisory Board Member Resigns Due to Conflict with Responsibilities with Important Public Sector Entity
15 oct. 2021 18h00 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, Oct. 15, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene modified cellular and immune therapies for infectious diseases and cancer, announced...
Fireside Chat with Enochian BioSciences’ CEO, Dr. Mark Dybul at H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference
12 oct. 2021 18h00 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, Oct. 12, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today...
Enochian BioSciences Announces Its Successful Completion of FDA Pre-IND for a Potential Cure for Hepatitis B Virus Infection
27 sept. 2021 07h00 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, Sept. 27, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today...
Enochian BioSciences to Present to Investors at the H.C. Wainwright 23rd Annual Investment Conference
13 sept. 2021 07h00 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will...